|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Itakura E, Huang RR, Wen DR, Paul E,
Wünsch PH and Cochran AJ: IL-10 expression by primary tumor cells
correlates with melanoma progression from radial to vertical growth
phase and development of metastatic competence. Mod Pathol.
24:801–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60.
2005. View Article : Google Scholar
|
|
4
|
Shi H, Hugo W, Kong X, Hong A, Koya RC,
Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al:
Acquired resistance and clonal evolution in melanoma during BRAF
inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar :
|
|
5
|
Puig-Butille JA, Escámez MJ, Garcia-Garcia
F, Tell-Marti G, Fabra À, Martínez-Santamaría L, Badenas C,
Aguilera P, Pevida M, Dopazo J, et al: Capturing the biological
impact of CDKN2A and MC1R genes as an early predisposing event in
melanoma and non melanoma skin cancer. Oncotarget. 5:1439–1451.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garbe C, Peris K, Hauschild A, Saiag P,
Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J,
Stratigos A, et al: Diagnosis and treatment of melanoma: European
consensus-based interdisciplinary guideline. Eur J Cancer.
46:270–283. 2010. View Article : Google Scholar
|
|
7
|
Loquai C, Schmidtmann I, Beutel M,
Sunderkötter C, Grabbe S, Schiller M and Nashan D: Quality of life
in melanoma patients during adjuvant treatment with pegylated
interferon-α2b: Patients' and doctors' views. Eur J Dermatol.
21:976–984. 2011.PubMed/NCBI
|
|
8
|
Dillman RO, DePriest C, Ellis R and de
Leon C: 5-year survival for patients with metastatic melanoma who
had no evidence of disease at time of treatment with patient
specific tumor stem cell vaccines. Cancer Research. 74:1972014.
View Article : Google Scholar
|
|
9
|
Di Lorenzo A and Bedford MT: Histone
arginine methylation. FEBS Lett. 585:2024–2031. 2011. View Article : Google Scholar
|
|
10
|
Wysocka J, Allis CD and Coonrod S: Histone
arginine methylation and its dynamic regulation. Front Biosci.
11:344–355. 2006. View
Article : Google Scholar
|
|
11
|
Yang Y and Bedford MT: Protein arginine
methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2013.
View Article : Google Scholar
|
|
12
|
Gu Z, Gao S, Zhang F and Wang Z, Ma W,
Davis RE and Wang Z: Protein arginine methyltransferase 5 is
essential for growth of lung cancer cells. Biochem J. 446:235–241.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshimoto T, Boehm M, Olive M, Crook MF,
San H, Langenickel T and Nabel EG: The arginine methyltransferase
PRMT2 binds RB and regulates E2F function. Exp Cell Res.
312:2040–2053. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM
and Zhu YJ: Identification of protein arginine methyltransferase 2
as a coactivator for estrogen receptor alpha. J Biol Chem.
277:28624–28630. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nicholas C, Yang J, Peters SB, Bill MA,
Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, et al: PRMT5 is
upregulated in malignant and metastatic melanoma and regulates
expression of MITF and p27 (Kip1). PLoS One. 8:e747102013.
View Article : Google Scholar
|
|
16
|
Nicholas C, Yan F, Peters SB, Bill MA, Li
P, Li C, Fuchs JR, Baiocchi R and Lesinski GB: The expression of
PRMT5 methyltransferase mediates cell survival and metastatic
phenotype in malignant melanoma. Cancer Research. 71:9332011.
View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shayan R, Karnezis T, Murali R, Wilmott
JS, Ashton MW, Taylor GI, Thompson JF, Hersey P, Achen MG, Scolyer
RA and Stacker SA: Lymphatic vessel density in primary melanomas
predicts sentinel lymph node status and risk of metastasis.
Histopathology. 61:702–710. 2012.PubMed/NCBI
|
|
20
|
Shields CL, Kaliki S, Furuta M, Fulco E,
Alarcon C and Shields JA: American Joint Committee on Cancer
classification of posterior uveal melanoma (tumor size category)
predicts prognosis in 7731 patients. Ophthalmology. 120:2066–2071.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krauthammer M, Kong Y, Ha BH, Evans P,
Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, et
al: Exome sequencing identifies recurrent somatic RAC1 mutations in
melanoma. Nat Genet. 44:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bao X, Zhao S, Liu T, Liu Y, Liu Y and
Yang X: Overexpression of PRMT5 promotes tumor cell growth and is
associated with poor disease prognosis in epithelial ovarian
cancer. J Histochem Cytochem. 61:206–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weichert W, Knösel T, Bellach J, Dietel M
and Kristiansen G: ALCAM/CD166 is overexpressed in colorectal
carcinoma and correlates with shortened patient survival. J Clin
Pathol. 57:1160–1164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Verma A, Shukla NK, Deo SV, Gupta SD and
Ralhan R: MEMD/ALCAM: A potential marker for tumor invasion and
nodal metastasis in esophageal squamous cell carcinoma. Oncology.
68:462–470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Degen WG, Van Kempen LC, Gijzen EG, van
Groningen JJ, van Kooyk Y, Bloemers HP and Swart GW: MEMD, a new
cell adhesion molecule in metastasizing human melanoma cell lines,
is identical to ALCAM (activated leukocyte cell adhesion molecule).
Am J Pathol. 152:805–813. 1998.PubMed/NCBI
|
|
28
|
Swart GW, Lunter PC, Kilsdonk JW and
Kempen LC: Activated leukocyte cell adhesion molecule
(ALCAM/CD166): Signaling at the divide of melanoma cell clustering
and cell migration? Cancer Metastasis Rev. 24:223–236. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lunter PC, Van Kilsdonk JW, Van Beek H,
Cornelissen IM, Bergers M, Willems PH, van Muijen GN and Swart GW:
Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a
novel actor in invasive growth, controls matrix metalloproteinase
activity. Cancer Res. 65:8801–8808. 2005. View Article : Google Scholar : PubMed/NCBI
|
